Chemotherapeutic efficacy of trimethoprim-sulfamethoxazole (Bactrim) in experimental murine toxoplasmosis

, Cho, Sung Won; , Yong, Tai Soon; , Chung, Pyung Rim; , Lee, Keun Tae

doi:1987.25.2.199

Korean J Parasito > Volume 25(2):1987 > Article

Original Article


Korean J Parasitol. 1987 Dec;25(2):199-206. English. Published online Mar 20, 1994. http://dx.doi.org/10.3347/kjp.1987.25.2.199
Copyright © 1987 by The Korean Society for Parasitology


Chemotherapeutic efficacy of trimethoprim-sulfamethoxazole (Bactrim) in experimental murine toxoplasmosis
Sung Won Cho,Tai Soon Yong,Pyung Rim Chung and Keun Tae Lee
Department of Parasitology, College of Medicine, Yonsei University, Seoul 120, Korea.



Abstract
The chemotherapeutic efficacy of trimethoprim-sulfamethoxazole (Bactrim) in mice experimentally infected with Toxoplasma gondii was evaluated. The average survival days and survival rate of mice infected intraperitoneally with 1 × 10(5) trophozoites and treated with Bactrim were compared with those of untreated group. The hematologic findings of blood samples of experimental mice were observed for comparison of side effects between Bactrim and pyrimethamine (Daraprim), the latter of which has been one of the favorable drugs for the treatment of toxoplasmosis. The results are summarized as follows: Bactrim showed a strong evidence of potent anti-Toxoplasma activity. The survival rate of mice administered with 24 mg of Bactrim per mouse per day for 7 days, was 83.3 percent, and the rate was increased to 100 percent in mice administered with two-fold concentrated dose of the drug. The average numbers of white blood cells (W.B.C.) in the mouse groups treated with Bactrim or Daraprim were more increased than those only infected with T. gondi. The mice treated with Daraprim, however, showed remarkably decreased numbers of W.B.C. as compared with those treated with Bactrim. The average numbers of red blood cells (R.B.C.) and platelets both in the drug-treated and untreated T. gondii-infected mice were decreased as compared with normal mice. The numbers of R.B.C. in Daraprim-treated mice, however, were more decreased than in Bactrim-treated mice. The average levels of hemoglobin both in the drug-treated and untreated T. gondii-infected mice were decreased, compared with normal mice. But there was no difference in the levels of hemoglobin between Bactrim- and Daraprim-treated groups. In conclusion, trimethoprim-sulfamethoxazole (Bactrim) was proven to be effective and safe for the treatment of murine toxoplasmosis. The efficacy was comparable with pyrimethamine (Daraprim), but bone marrow depression was less severe with Bactrim treatment.

Figures


	Fig. 1 Cumulatives survival rate (%) curve in control and experimental mice groups infected intraperitoneally with 1×10⁵ trophozoites of T. gondii and administered with Bactrim for 7 days. I: 6 mg of Bactrim/mouse/day, II: 12mg, III: 24mg, IV: 48mg, V: Control (normal), and VI: Control (infected & untreated)


	Fig. 2 Changes of W.B.C. and R.B.C. counts in mice infected with T. gondii and administered with Bactrim or Daraprim +Sulxin.


	Fig. 3 Changes of hemoglobin and platelet counts in mice infected with T. gondii and administered with Bactrim or Daraprim +Sulxin.

Tables


	Table 1 Effect of Bactrim in mice infected intraperitoneally with 1×10⁵T. gondii trophozoites^*


	Table 2 Hematologic findings in mice infected with T. gondii and daily administered per os with anti- Toxoplasma drugs for 25 days following 3 days after infection


	Table 3 Changes of white blood cells (W.B.C), red blood cells (R.B.C), hemoglobin and platelet counts in mice infected intraperitoneally with 1×10⁵ trophozoites of T. gondii and untreated


	Table 4 Changes of W.B.C., R.B.C., hemoglobin and platelet counts in mice infected with T. gondii and daily administered per os with Bactrim for 25 days following 3 days after infection (24 mg/mouse/day)


	Table 5 Changes of W.B.C., R.B.C., hemoglobin and platelet counts in mice infected with T. gondii and daily administered per os with Daraprim and Sulxin^* for 25 days following 3 days after infection

References


1.	Abell C, Holland P. Acute toxoplasmosis complicating leukemia. Diagnosis by bone marrow aspiration. Am J Dis Child 1969;118(5):782–787.

2.	Bartlett JG, Chang TW, Gurwith M, Gorbach SL, Onderdonk AB. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 1978;298(10):531–534.

3.	Bushby SR, Hitchings GH. Trimethoprim, a sulphonamide potentiator. Br J Pharmacol Chemother 1968;33(1):72–90.

4.	Choi JS, et al. Yonsei Rep Trop Med 1980;11(1):39–42.

5.	Choi WY, Yoo JU, Kim WG. [Toxoplasma antibodies by indirect latex agglutination tests in St. Mary's Hospital patients]. Korean J Parasitol 1982;20(1):33–37.

6.	Choi WY, Yoo JE, Chung CS, Paik KK, Cho SN. [Toxoplasma Antibodies By Indirect Latex Agglutination Tests In National Seoul Mental Hospital Patients]. Korean J Parasitol 1983;21(2):281–285.

7.	Christiansen M, Siim JC. Toxoplasmosis in hares in Denmark. Serological identity of human and hare strains of toxoplasma. Lancet 1951;1(6666):1201–1203.

8.	Chung KS, et al. Yonsei Med J 1980;21(1):62–71.

9.	Chung PR, et al. Yonsei Rep Trop Med 1975;6(1):31–36.

*10.*	Frenkel JK, et al. Antib and Chemo 1957;VII(12):630–638.

*11.*	Jacobs L. Toxoplasma and toxoplasmosis. Adv Parasitol 1967;5:1–45.

*12.*	Jyono K, et al. J Osaka City Med Cent 1958;7(8):19–23.

*13.*	Lakhanpal V, Schocket SS, Nirankari VS. Clindamycin in the treatment of toxoplasmic retinochoroiditis. Am J Ophthalmol 1983;95(5):605–613.

*14.*	Nguyen BT, Stadtsbaeder S. In vitro activity of cotrimoxazole on the intracellular multiplication of Toxoplasma gondii. Pathol Eur 1975;10(4):307–315.

*15.*	Nguyen BT, Stadtsbaeder S. Comparative effects of cotrimoxazole (trimethoprim-sulphamethoxazole), pyrimethamine-sulphadiazine and spiramycin during avirulent infection with Toxoplasma gondii (Beverley strain) in mice. Br J Pharmacol 1983;79(4):923–928.

*16.*	Norrby R, Eilard T, Svedhem A, Lycke E. Treatment of toxoplasmosis with trimethoprim-sulphamethoxazole. Scand J Infect Dis 1975;7(1):72–75.

*17.*	Rubin RH, Swartz MN. Trimethoprim-sulfamethoxazole. N Engl J Med 1980;303(8):426–432.

*18.*	Sander J, Midtvedt T. The effect of trimethoprim on acute experimental toxoplasmosis in mice. Acta Pathol Microbiol Scand B Microbiol Immunol 1970;78(6):664–668.

*19.*	Soh CT, et al. Yonsei Med J 1960;1:52–54.

*20.*	Soh CT, et al. Yonsei Rep Trop Med 1975;6(1):23–30.

*21.*	Tabbara KF, O'Connor GR. Treatment of ocular toxoplasmosis with clindamycin and sulfadiazine. Ophthalmology 1980;87(2):129–134.

*22.*	Thiermann E, Apt W, Atias A, Lorca M, Olguín J. A comparative study of some combined treatment regimens in acute toxoplasmosis in mice. Am J Trop Med Hygq 1978;27(4):747–750.

*23.*	Watanabe Y. J Osaka City Med Cent 1960;9(6):209–225.

*24.*	Wormser GP, Keusch GT. Trimethoprim-sulfamethoxazole in the United States. Ann Intern Med 1979;91(3):420–429.